Table 4.
Distribution of positive rates and antibody levels for IgG subtypes and neutralizing antibodies.
| RBD-IgG positive number(%) | P | S-IgG positive number(%) | P | N-IgG positive number(%) | P | Nab positive number(%) | P | RBD-IgG antibody levels (mean,95%CI) | P | S-IgG antibody levels (mean,95%CI) | P | N-IgG antibody levels (mean,95%CI) | P | Nab antibody levels (mean,95%CI) | P | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | 284(89.31) | 291(91.51) | 251(78.93) | 264(83.02) | 11.37(10.00,12.74) | 15.27(13.46,17.08) | 9.02(7.54,10.50) | 18.13(16.31,19.96) | ||||||||
| Gender | 0.150 | 0.188 | 0.701 | 0.449 | 0.677 | 0.530 | 0.901 | 0.247 | ||||||||
| Male | 130(86.67) | 134(89.33) | 117(78.00) | 122(81.33) | 11.05(8.85,13.25) | 14.65(11.78,17.51) | 9.12(6.80,11.44) | 16.98(14.36,19.59) | ||||||||
| Female | 154(91.67) | 157(93.45) | 134(79.76) | 142(84.52) | 11.64(9.89,13.38) | 15.80(13.49,18.12) | 8.93(7.00,10.85) | 19.13(16.57,21.69) | ||||||||
| Age (ys) | 0.603 | 0.422 | <0.001*** | 0.505 | 0.137 | 0.088 | 0.005** | 0.708 | ||||||||
| <20 | 15(88.24) | 15(88.24) | 7(41.48) | 14(82.35) | 5.85(2.57,9.12) | 8.26(3.56,12.96) | 3.39(1.70,5.07) | 12.67(4.61,20.72) | ||||||||
| 20~ | 28(87.50) | 28(87.50) | 22(68.75) | 26(81.25) | 11.48(5.34,17.62) | 14.42(7.31,21.52) | 5.56(2.92,8.20) | 16.33(9.96,22.70) | ||||||||
| 30~ | 67(84.81) | 69(87.34) | 59(74.68) | 62(78.48) | 9.83(7.61,12.05) | 12.58(9.80,15.36) | 5.60(4.33,6.87) | 18.83(14.95,22.71) | ||||||||
| 40~ | 50(92.59) | 50(92.59) | 47(87.04) | 44(81.48) | 11.05(8.29,13.80) | 15.42(11.29,19.56) | 9.54(6.59,12.49) | 19.26(15.01,23.50) | ||||||||
| 50~ | 69(93.24) | 71(95.95) | 63(85.14) | 67(90.54) | 14.15(10.52,17.77) | 19.13(14.50,23.77) | 13.22(9.01,17.44) | 19.10(15.29,22.91) | ||||||||
| ≥60 | 55(88.71) | 58(93.55) | 53(85.48) | 51(82.26) | 11.51(8.85,14.16) | 15.84(11.97,19.71) | 9.53(5.89,13.17) | 17.47(13.22,21.72) | ||||||||
| Severity of disease | 0.003** | 0.013* | <0.001*** | 0.004** | 0.184 | 0.116 | 0.349 | 0.106 | ||||||||
| Asymptomatic type | 73(79.35) | 77(83.70) | 57(61.96) | 66(71.74) | 8.76(6.68,10.84) | 11.65(8.84,14.46) | 7.45(5.11,9.80) | 14.41(11.16,17.67) | ||||||||
| Mild type | 57(95.00) | 58(96.67) | 54(90.00) | 55(91.67) | 12.33(9.81,14.85) | 17.15(13.74,20.56) | 10.94(7.14,14.74) | 19.37(15.05,23.69) | ||||||||
| Normal type | 150(92.59) | 152(93.83) | 136(83.95) | 139(85.80) | 12.26(10.06,14.46) | 16.27(13.41,19.13) | 8.75(6.69,10.81) | 19.20(16.64,21.76) | ||||||||
| Severe/Critical type | 4(100.00) | 4(100.00) | 4(100.00) | 4(100.00) | 12.04(6.61,17.47) | 19.70(3.52,35.88) | 14.48(-5.26,34.22) | 25.64(-0.51,51.79) | ||||||||
| SARS-CoV-2 vaccination | 0.711 | 0.878 | 0.193 | 0.285 | 0.003** | 0.0001*** | <0.001*** | <0.001*** | ||||||||
| Unvaccinated | 244(89.05) | 251(91.61) | 213(77.74) | 225(82.12) | 10.54(9.06,12.02) | 13.86(11.99,15.74) | 7.33(6.03,8.62) | 16.11(14.21,18.01) | ||||||||
| Vaccinated | 40(90.91) | 40(90.91) | 38(86.36) | 39(88.64) | 16.41(12.97,19.85) | 24.11(18.81,29.40) | 18.50(12.60,24.40) | 29.83(25.62,34.04) | ||||||||
| Months after symptom onset | 0.029* | 0.144 | 0.014* | 0.002** | 0.104 | 0.074 | 0.850 | 0.0007*** | ||||||||
| 9~10M | 8(100.00) | 8(100.00) | 8(100.00) | 8(100.00) | 5.43(1.46,9.40) | 8.55(2.56,14.54) | 5.82(1.33,10.32) | 13.83(1.97,25.69) | ||||||||
| 11~12M | 7(63.64) | 8(72.73) | 5(45.45) | 6(54.55) | 17.91(0.28,35.54) | 21.82(0.02,43.62) | 10.46(0.37,20.55) | 13.69(-0.95,28.34) | ||||||||
| 13~14M | 64(86.49) | 67(90.54) | 57(77.03) | 54(72.97) | 9.05(6.92,11.18) | 11.89(9.20,14.58) | 8.18(5.43,10.93) | 12.82(9.28,16.36) | ||||||||
| 15~16M | 195(90.70) | 198(92.09) | 171(79.53) | 186(86.51) | 12.02(10.25,13.80) | 16.07(13.74,18.40) | 9.27(7.33,11.20) | 19.20(17.00,21.39) | ||||||||
| 17~18M | 10(100.00) | 10(100.00) | 10(100.00) | 10(100.00) | 13.62(8.60,18.64) | 22.24(13.20,31.28) | 11.34(4.13,18.54) | 33.21(23.92,42.50) |
P < 0.05 represents significant difference. *p <0.05; **p<0.01; ***p<0.001; ****p<0.0001.